


**ONCOENDOCRINOLOGY SPECIAL  
INTEREST GROUP LEADERSHIP**





**Ole-Petter Hamnvik, MBBCH, BAO**  
SIG Co-Chair  
Endocrinologist  
Brigham and Women's Hospital

Dr. Hamnvik is an Assistant Professor of Medicine at Harvard Medical School and the director of the BWH/DFCI Center for Onco-endocrinology. In this capacity, he provides clinical care to cancer patients with a variety of endocrine disorders, he develops clinical pathways for management of common endocrinopathies in cancer patients, and he studies the impact of various oncologic therapies on endocrine outcomes. In addition to his clinical-administrative role with this center, he is also an educator who directs the endocrinology fellowship program at BWH and serves as the Education Editor for NEJM Group.



**Afreen Shariff, MD, MBBS**

SIG Co-Chair

Diabetes and Metabolism Specialist  
Duke Cancer Institute, Duke University

Dr. Shariff is an Assistant Professor of Medicine, Director of the Duke Endo-Oncology Program and the Associate Director at the Center for Cancer Immunotherapy at the Duke Cancer Institute where she manages the Multi-Disciplinary Toxicity Program. She focuses on patient centric clinical programs targeted at improving access and reducing healthcare utilization related to endocrine emergencies in cancer patients. Her current projects include (1) the effective use of electronic consultative services to reduce access time and (2) developing AI assisted clinical decision tools that provide patient specific prediction of immune related adverse events.



**Yee-Ming Melody Cheung, MBBS, PhD**  
Endocrinologist  
Austin Health  
Brigham and Women's Hospital

Dr. Cheung is an Academic Endocrinologist at the University of Melbourne, and a Clinical Research Fellow at the Brigham and Women's Hospital, Harvard Medical School. Her clinical and research work has been focused on onco-endocrinology and she is currently completing a PhD investigating the effects and management of cardiometabolic disorders associated with breast cancer therapies.



**Emily Gallagher, MD, PhD**  
Assistant Professor  
Icahn Mount Sinai Hospital

Dr. Gallagher is an Assistant Professor of Medicine, member of the Tish Cancer Institute and Director of the American Board of Internal Medicine Research Pathway for residents at the Icahn School of Medicine at Mount Sinai. She is an NIH-funded physician-scientist whose translational research involves understanding the mechanisms through which dyslipidemia and hyperinsulinemia impact cancer progression, as well as the metabolic and endocrine effects of novel cancer therapies. In her onco-endocrinology clinical practice she treats metabolic and endocrine disorders that occur in individuals with cancer, or as a result of cancer treatment.